EMERYVILLE, Ca., Jan. 24,
2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq:
AMRS), a leading synthetic biotechnology company accelerating the
world's transition to sustainable consumption through its
Lab-to-Market™ operating platform announces that it has agreed
to exclusive terms to acquire the assets of MenoLabs, LLC, a
women-founded company to treat menopause symptoms, drive research
for women's health and improve society's understanding of
menopause.
Amyris previously communicated its intention of launching a new
consumer brand to provide science-backed, wellness and personal
care products for the high growth menopause market in 2022. The
acquisition of MenoLabs will serve as a catalyst to accelerate
growth and establish a leadership position in the fast-growing
menopause market.
MenoLabs, a growing women's wellness brand is focused on
addressing perimenopause and menopause symptoms. MenoLabs is one of
few companies offering research-backed all-natural treatments of
menopause symptoms. Over the past two years, MenoLabs has developed
and launched eight products, including its lead product, MenoFit,
an all-natural menopause relief supplement. MenoLabs generates a
subscription-based, recurring revenue stream via its website, in
addition to the Subscribe & Save option offered via the Amazon
channel. The company is further expanding its omnichannel by
penetrating retail channels in 2022. Additionally, MenoLabs
launched MenoLife, a highly rated perimenopause and menopause
health tracker app which helps users track and analyze more than 40
menopause-related symptoms. MenoLife also has created an online
forum where users can comment and react to posts.
Menopause symptoms impact the lives of approximately 25 million
women per year and 6,000 women in the U.S. enter perimenopause
every day (2.2 million each year). By 2025, there will be over one
billion people experiencing menopause in the world or around 12% of
the entire world population. Stigma, lack of open discussion, and a
small product offering at an affordable price are barriers to care
for women. The menopause market was valued at around $15 billion in 2020 and is expected to reach
approximately $23 billion by
2028.
"We are very impressed with the MenoLabs offering which is
synergistic with our science-based approach to real-world health
and wellness issues. We are committed to empowering women and
creating a platform to support them with our leading science and
wellness technology platform. Women deserve products and solutions
that work during this period in their lives," said John Melo, President and Chief Executive Officer
of Amyris. "Our acquisition of the products and app that the
MenoLabs team has built accelerates Amyris' entry into the
menopause market. We expect the combination of MenoLabs and the
previously announced menopause brand with Naomi Watts to have the potential to deliver an
estimated $30 million in revenue in
their first year and expect significant growth potential in the
years ahead. We continue to execute on our growth strategy
diversifying our consumer offering in Clean Beauty, Health and
Wellness end-markets, continuing the strong growth momentum from
2021 into the current quarter."
About Amyris
Amyris (Nasdaq: AMRS) is a leading
synthetic biotechnology company, transitioning the Clean Health
& Beauty and Flavors & Fragrances markets to sustainable
ingredients through fermentation and the company's proprietary
Lab-to-Market™ operating platform. This Amyris platform
leverages state-of-the-art machine learning, robotics and
artificial intelligence, enabling the company to rapidly bring new
innovation to market at commercial scale. Amyris ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris also owns and
operates a family of consumer brands that is constantly evolving to
meet the growing demand for sustainable, effective and accessible
products. For more information, please visit
http://www.amyris.com.
Amyris, the Amyris logo and Lab-to-Market are trademarks or
registered trademarks of Amyris, Inc. in the U.S. and/or other
countries.
About MenoLabs
MenoLabs was founded to
fundamentally change how menopause is addressed. The brand's
mission is to provide options to treat menopause symptoms, drive
research for women's health and change how society approaches,
views and educates around the topic of menopause. MenoLabs has
developed a line of all natural, proprietary supplements focused on
treating perimenopause and menopause symptoms, in addition to
MenoLife, a leading menopause health tracker app that provides
women a voice and community. MenoLife also provides symptom
tracking to further fuel research and advancements in women's
health.
Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events,
such as the planned closing of the acquisition of MenoLabs assets
and the timing thereof; Amyris' expectation that the MenoLabs
acquisition will accelerate its entry into and establish Amyris'
leadership position in the menopause market and diversify its
consumer offerings; Amyris' expectations regarding the potential
initial year revenue and growth of the MenoLabs and previously
announced menopause brand with Naomi
Watts, and potential growth of the menopause market; and
Amyris' expectation of continued consumer revenue growth momentum
from 2021 into the first quarter of 2022. These statements are
based on management's current expectations and actual results and
future events may differ materially due to risks and uncertainties,
including risks related to the Amyris' liquidity and ability to
fund operating and capital expenses, risks related to potential
delays or failures in completing and integrating planned
acquisitions, risks related to potential delays or failures in
development, regulatory approval, launch, production and
commercialization of products, , risks related to reliance on third
parties particularly in the supply chain, and other risks detailed
from time to time in filings Amyris makes with the Securities and
Exchange Commission, including Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The
companies disclaim any obligation to update information contained
in these forward-looking statements, whether as a result of new
information, future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-to-acquire-menolabs-for-menopause-wellness-accelerating-growth-of-consumer-business-301466348.html
SOURCE Amyris, Inc.